AUG 11, 2026 · PHASE 1/2 TRIAL
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
ClinicalTrials.gov
This is a Phase 1/2 trial registration with no reported results; the study is actively recruiting and has not yet established safety, tolerability, or efficacy of the combination.
Reported
Estimated enrollment62
PhasePhase 1/Phase 2
Primary endpoint (Phase 1)Recommended Phase II dose of bexmarilimab i…